Loading
Liver Disease Diagnosis and Treatment · Journal article
Revista Ibero-americana De Humanidades, Ciências E Educação · August 10, 2026
Reinforces what was already believed, rather than introducing something new.
This narrative review of 43 clinical trials confirms that obesity and visceral/abdominal adiposity are central to MASLD pathogenesis, and that weight loss, reduced waist circumference, decreased visceral fat, and improved insulin resistance associate with reductions in hepatic fat, steatosis, and metabolic markers. The evidence supports prioritizing sustainable weight loss and metabolic control, though the authors note variable but clinically relevant results from incretin agonists, metabolic modulators, and some nutraceuticals in specific subgroups.
Narrative literature review. Clinical trials and studies examining the association between obesity/abdominal obesity/adiposity and MASLD, with evaluation of interventions and hepatic or metabolic outcomes. Intervention: Dietary and lifestyle interventions, incretin agonists, metabolic modulators, and nutraceuticals.
Weight reduction, waist circumference reduction, visceral fat reduction, and insulin resistance improvement were associated with reductions in hepatic fat, steatosis, and metabolic markers Dietary and lifestyle interventions were frequent across included studies Incretin agonists, metabolic modulators, and some nutraceuticals showed variable but clinically relevant results in subgroups
Variable results in pharmacological subgroups noted but not quantified
Clinicians should recognize that sustainable weight loss, reduction of abdominal/visceral adiposity, and metabolic control form the foundation of MASLD management. Interventions should be individualized, with consideration of dietary and lifestyle modification as primary strategies, and potential adjunctive roles for incretin agonists or metabolic modulators in selected patients.
A narrative literature review synthesizing 43 clinical trials and studies confirming the established association between obesity/adiposity and MASLD, with evidence that weight loss and metabolic improvements reduce hepatic steatosis.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that sustainable weight loss, reduction of abdominal/visceral adiposity, and metabolic control form the foundation of MASLD management. Interventions should be individualized, with consideration of dietary and lifestyle modification as primary strategies, and potential adjunctive roles for incretin agonists or metabolic modulators in selected patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introdução: A doença hepática esteatótica associada à disfunção metabólica (MASLD) é uma condição cada vez mais reconhecida na prática clínica e apresenta forte relação com obesidade, adiposidade visceral, resistência à insulina e risco cardiometabólico. Apesar disso, diferentes estudos têm mostrado que a melhora hepática pode depender tanto da perda de peso quanto de mudanças qualitativas na dieta, na composição corporal e no metabolismo. Objetivo: Analisar, por meio de revisão narrativa, a relação entre obesidade/adiposidade e MASLD, destacando fatores associados, intervenções avaliadas em ensaios clínicos e principais desfechos hepáticos e metabólicos. Métodos: Foi realizada busca no PubMed em 29/07/2026, utilizando a estratégia: ("Metabolic Dysfunction-Associated Steatotic Liver Disease" OR MASLD) AND ("Obesity" OR "Abdominal Obesity" OR Adiposity) AND ("Risk Factors" OR Association OR Prevalence). Foram aplicados filtros para Clinical Trial, Randomized Controlled Trial e últimos 10 anos. Após triagem de 60 registros, 43 estudos foram incluídos na síntese, sendo 35 no núcleo principal e 8 como apoio. Resultados: Os estudos indicaram que redução de peso, circunferência abdominal, gordura visceral e melhora da resistência à insulina se associaram a reduções de gordura hepática, esteatose e marcadores metabólicos. Intervenções dietéticas e de estilo de vida foram frequentes, enquanto agonistas incretínicos, moduladores metabólicos e alguns nutracêuticos apresentaram resultados variáveis, porém clinicamente relevantes em subgrupos. Conclusão: A obesidade e a adiposidade, especialmente visceral/abdominal, constituem elementos centrais na MASLD. O manejo deve priorizar perda ponderal sustentável, melhora da composição corporal, controle metabólico e individualização terapêutica.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.